Compare CMTL & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | CELU |
|---|---|---|
| Founded | 1967 | 2016 |
| Country | United States | United States |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1M | 34.5M |
| IPO Year | 2024 | N/A |
| Metric | CMTL | CELU |
|---|---|---|
| Price | $5.11 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | $6.00 |
| AVG Volume (30 Days) | ★ 225.6K | 28.0K |
| Earning Date | 03-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $499,528,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.97 | $76.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.19 | $1.01 |
| 52 Week High | $6.21 | $4.35 |
| Indicator | CMTL | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 48.72 |
| Support Level | $4.86 | $1.21 |
| Resistance Level | $6.15 | $1.33 |
| Average True Range (ATR) | 0.35 | 0.12 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 20.91 | 40.90 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.